Peer-reviewed veterinary case report
Tepoxalin causes cell death in cat oral squamous cell cancer cells
By Wakshlag, Joseph J et al.·Published in American journal of veterinary research·2011·College of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
- Species:
- cat
Plain-English summary
A study looked at squamous cell carcinomas (SCCs) in cats, particularly focusing on how a specific enzyme called 5-lipoxygenase behaves in these tumors. Researchers found that oral SCCs showed the highest levels of this enzyme. When they tested a drug called tepoxalin, which inhibits 5-lipoxygenase, it caused cancer cells to die in the lab. This suggests that tepoxalin might be a promising treatment for cats with oral SCCs, although more research is needed to confirm its safety and effectiveness in real-life situations.
People also search for: cat oral cancer treatment · squamous cell carcinoma in cats · tepoxalin for cats · 5-lipoxygenase in feline cancer
Abstract
OBJECTIVE: To assess expression pattern and subcellular compartmentalization of 5-lipoxygenase in cutaneous, UV radiation-induced, and oral squamous cell carcinomas (SCCs) in cats and determine the effects of cyclooxygenase or 5-lipoxygenase inhibition on proliferation or apoptosis in a feline oral squamous cell carcinoma (SCCF1) cell line. SAMPLE: 60 archived paraffin-embedded samples of SCCs from 60 cats and SCCF1 cells. PROCEDURES: Retrospective immunohistochemical analysis of the archived samples of SCCs (20 cutaneous, 20 UV radiation-induced, and 20 oral tumors) was performed. Cell culture proliferation assays involving SCCF1 cells were performed, and tepoxalin-induced apoptosis and signaling were examined via western blotting and annexin V staining. RESULTS: Immunohistochemically, staining for 5-lipoxygenase was most frequently of greatest intensity in oral SCCs, whereas staining of cutaneous and UV radiation-induced lesions had less consistent 5-lipoxygenase expression. Exposure of SCCF1 cells to the 5-lipoxygenase inhibitor tepoxalin resulted in apoptosis; the effect appeared to be mediated via alteration of cell signaling rather than via suppression of lipid mediators that are typically produced as a result of 5-lipoxygenase activity. CONCLUSIONS AND CLINICAL RELEVANCE: In cats, expression of 5-lipoxygenase in SCCs appeared to differ depending on tumor location. The influence of tepoxalin-induced 5-lipoxygenase inhibition on a 5-lipoxygenase-expressing cell line coupled with the notable expression of 5-lipoxygenase in oral SCCs suggested that 5-lipoxygenase inhibition may have therapeutic benefits in affected cats. Although the safety of tepoxalin in cats has yet to be investigated, 5-lipoxygenase inhibitors should be evaluated for use as a potential treatment for SCCs in that species.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21962280/